Targovax ASA: Interim Report second quarter and first half

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Targovax ASA: Interim Report second quarter and first half year 2016

OSLO, Norway, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below).

Highlights:

  • Recruited and dosed the first patient in the Phase Ib/II trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with chemotherapy  
  • Reported encouraging interim immunological response from the second cohort of the Phase I/II TG01 trial, assessing early immune activation  
  • Completed recruitment in the open label Phase I/II TG01 trial in combination with chemotherapy of patients with resected pancreatic cancer. 32 patients are included in this trial  
  • Confirmed synergism between ONCOS-102 and chemotherapy through in vivo research and published data in The International Journal of Cancer  
  • Received US patent for lead viral product ONCOS-102  
  • Raised NOK 110m in new equity, securing funding for further development of the company's ongoing and planned trials  
  • In July, listed the shares on Oslo Axess, and raised NOK 4m in a subsequent repair offering in August  
  • Second quarter 2016 operating expenditures of NOK 32m. Cash holdings were at the end of the quarter, before the financing, NOK 107m

         Preparation of new combination clinical trials progressed according to plan. At the moment four new studies are in the process of being set up. In June Targovax recruited and dosed the first patient in the Phase Ib/II trial evaluating ONCOS-102 for the treatment of malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the lung, in combination with chemotherapy. This trial is planned to include six patients in the lead-in for safety evaluation of the combination treatment, and approximately 24 patients in a randomized second part to compare the tumor targeted immune activation of the combination treatment with the standard of care chemotherapy.

In July 2016, Targovax raised NOK 110 million in new equity. The transaction closed on 7 July 2016 and Targovax listed the next day on Oslo Axess under the ticker TRVX.

"Targovax develops according to plan. I am especially pleased that we recruited our first patient in our mesothelioma trial and that we could present positive data for our peptide immune therapy. The recent IPO means that we have funding to start and get data from six new trials", says CEO Gunnar Gårdemyr.

###

Presentation The presentation will take place at 10:00 CET at:

Hotel Continental Stortingsgaten 24/26 0117 Oslo

The presentation will also be webcast live and can be accessed through www.targovax.com .

Conference call At 14:00 CET (08:00 EST) The company will host a telephone conference which will include a presentation of the results, following a Q&A session.  CEO Gunnar Gårdemyr and CFO Øystein Soug will present the company.  Call in details can be found below.

Call-in numbers: Norway Toll-Free Number: 800 19 747 Norway Toll Number: +472350 0559 UK Toll-Free Number: 08082370030 UK Toll Number: +442031394830 US Toll-Free Number: 1866 928 7517 US Toll Number: +1 718 873 9077

Access code: 72735642#

Please make sure to dial in at least 5-10 minutes ahead to complete your registration.

See attached list for more dial-in numbers. http://events.arkadin.com/ev/docs/NE_FEL_Even...s_List.pdf

Reporting material The quarterly report and presentation are also available at the website   www.targovax.com .

For further information, please contact

Gunnar Gårdemyr, CEO Phone: +41 798 340 585 Email: ggardemyr@targovax.com

Øystein Soug, CFO Phone: +47 906 56 525 Email: oystein.soug@targovax.com

Arming the patient's immune system to fight cancer Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS-102  is a product candidate derived from a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

The product candidates TG01 and TG02 constitute a peptide-based immunotherapy platform  targeting the difficult to treat RAS mutations  found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Targovax_Second quarter and first half 2016 report http://hugin.info/171039/R/2037133/758988.pdf Targovax_Second quarter and first half 2016 presentation http://hugin.info/171039/R/2037133/758989.pdf

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 68

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Franklin County Trees Raise Funds and Honor Veterans

Updated Category News Views 66

Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 103

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Senior Living: The BrainFit Gym Experience

Updated Category News Views 330

Introducing the BrainFit Gym at The Bristal The Bristal Assisted Living is taking a bold step towards promoting cognitive wellness among seniors with their newly launched BrainFit Gym. Located at The Bristal at York Avenue, this unique facility stands out as a pioneering initiative aimed at enhancing the mental capacities of its residents. With this innovative approach,...

Continue Reading
Bullish (BLSH) Stock Surges After Thrilling IPO Success

Updated Category News Views 262

Bullish Stock Makes a Remarkable Entrance on the Market Recently, the cryptocurrency exchange Bullish (BLSH) took the public market by storm with its much-anticipated initial public offering (IPO). Its shares soared following trading debut, generating excitement among investors and analysts alike. Key Highlights of the IPO Supported by the renowned billionaire venture...

Continue Reading
Medius Honored as Top Microsoft Partner for Innovative Finance

Updated Category News Views 118

Medius Named 2024 Microsoft ISV Partner of the Year Medius, a leader in Accounts Payable (AP) Automation and Spend Management solutions, has reached an impressive milestone by being honored as the 2024 Microsoft ISV Partner of the Year. This esteemed award showcases Medius' dedication to innovation and excellence in improving finance operations through technology. The...

Continue Reading
Day One Biopharmaceuticals Set to Reveal Q1 2025 Financials

Updated Category News Views 309

Day One Biopharmaceuticals Plans Q1 2025 Financial Report Day One Biopharmaceuticals (NASDAQ: DAWN) is gearing up for a significant event. The biopharmaceutical company, known for its dedication to developing targeted therapies for serious illnesses, has announced a live conference call and webcast set for early May 2025. This event offers a chance for stakeholders to...

Continue Reading
Navigating the Future of Nonprofit Fundraising in 2025

Updated Category News Views 441

Nonprofit Fundraising Trends for 2025 As we approach the year 2025, nonprofits are setting their sights on innovative tactics that will not only enhance their fundraising efforts but also embrace the changing dynamics of donor engagement. Recent insights reveal that the landscape of nonprofit fundraising is evolving, making adaptability a core component of success in the...

Continue Reading